Coronavirus / COVID

Heat Biologics CEO Jeff Wolf talks with Contagion about the firm's effort to develop a vaccine for the coronavirus which can potentially be administered for some seniors by taking advantage of prior immune mechanisms.

One effort to develop a SARS-CoV-2 vaccine focuses on combining antibody and T cell immunity, using a gp96 protein based technology.

The company is recruiting up to 30000 Americans for AZD1222, its vaccine candidate, as it enters a late-stage trial.

A new analysis of excess deaths suggests the peak of the current pandemic in New York City had a death rate in the same league as the infamous 1918 influenza pandemic.

A new CDC Morbidity and Mortality Weekly Report adds information on seroprevalence of SARS-CoV-2 among health care workers in a 13-hospital multistate medical network between April and June of 2020.

A study team examined asthma prevalence in patients hospitalized for COVID-19 with population asthma prevalence and a 4-year average of asthma prevalence in influenza hospitalizations across the United States.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at USP, discusses the recent report of SARS-CoV-2 reinfection.

Mathematical modeling for tracing COVID-19 contacts can account for likely scenarios of inconsistent physical distancing and quarantine adherence

An estimate that 100K may have been infected by mid-March dwarfs official figures.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia, explains the fundamentals of convalescent plasma treatment for COVID-19.

Bhopal’s recent article, COVID-19 Zugzwang, was published in Public Health in Practice.

FDA expands usage to all hospitalized COVID-19 patients.

The 15-minute test was granted emergency authorization by the FDA earlier this week.

John F. Kokai-Kun, PhD, explains the supply chain and logistical issues limiting the scale of monoclonal antibody treatment.

John F. Kokai-Kun, PhD, Director of External Scientific Collaboration at US Pharmacopeia, explains the fundamentals of monoclonal antibody treatment.

The short-lived designation of remdesivir as an Orphan Drug to treat COVID-19 exposed loophole in the Orphan Drug Act.

How can critically ill COVID-19 patients experience immune system “paralysis” when inflammatory processes are in overdrive?

Hospital admissions for stroke fell by nearly a third during March and April 2020 alone when compared with those months in 2019.

A study team assessed 4 methods of N95 mask decontamination, with results suggesting that proper procedure can allow the reuse of masks 2-3 times.

Martin Kulldorff, PhD, explains that masks can't replace social distancing for those at highest risk for severe COVID-19.

Drug has shown promise in COVID-19, but other, oral options are needed.

The device has test result features likened to pregnancy tests, and can be produced vastly every month.

Brad Spellberg, MD, explains how real progress can be made to a debted system with worsened rates of user health.

Martin Kulldorff, PhD, answers whether an age based coronavirus strategy would worsen the pandemic's impact on workers and minority racial groups.

Investigators report comparable SARS-CoV-2 neutralizing antibody counts across age groups, as well as favorable safety outcomes for the two-dose vaccine.

Soon after visiting 38 hospitals in Michigan, over half of patients hospitalized with suspected COVID-19 received antibiotics.

The US Centers for Disease Control and Prevention has updated COVID-19 guidance, sharing advice on safe travel

Martin Kulldorff, PhD, takes a total social health perspective on the global use of mass quarantines as a primary COVID-19 control strategy.

Brad Spellberg, MD, discusses how the subspecialty lost "ownership" of its opportunities for pattented prescribing and referral years ago.

Company says investigational therapeutic could afford at least 6 months of protection from the virus.